GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024
- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- GemVax & KAEL Co., Ltd. ("GemVax"; KOSDAQ ticker: 082270) announced that topline results of a Phase 2a clinical trial (the "Phase 2a PSP Clinical...
Discovery of cancer risk associations for six novel genes
REYKJAVIK, Iceland, Oct. 29, 2024 /PRNewswire/ --Scientists at deCODE genetics/Amgen, and their collaborators have discovered six novel genes with rare germline variants that associate with cancer risk. The findings are published today in Nature Genetics under the title "Gene-based burden tests of rare germline variants identify six cancer susceptibility genes". Kari Stefansson senior author of the...
Regional and Global Experts Convene in Accra, Ghana to Update Cancer Treatment Guidelines for Sub-Saharan Africa
Ongoing international oncology collaboration works to empower health care workers and save lives across diverse resource environments. Accra, GHANA, Oct. 29, 2024 /PRNewswire/ -- International oncology experts are gathering in Accra, Ghana for a series of meetings beginning today, to update cancer treatment recommendations in the NCCN Harmonized Guidelines™ for Sub-Saharan Africa....
Virtus Fertility Centre Singapore Expands its Medical Team with the addition of fertility specialist Dr. Tan Heng Hao.
VFCS looks to strengthen further its value of care and patients' experience with Dr. Tan's added specialty and focus on fertility treatments and minimally invasive gynaecological surgeries. SINGAPORE, Oct. 29, 2024 /PRNewswire/ -- Virtus Fertility Centre Singapore is pleased to announce that Dr. Tan Heng Hao, a specialist in fertility care and...
RemeGen Announces the Acceptance of the Marketing Application of Telitaccept for the Treatment of Myasthenia Gravis in China
YANTAI, China, Oct. 29, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing application of Taicercept ® for the treatment of generalized myasthenia gravis (gMG) has been officially accepted by the Center for Drug Evaluation (CDE) of the China National...
The 21st World Congress of Chinese Medicine – Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases Kicks off in Paris
PAIRS, Oct. 29, 2024 /PRNewswire/ -- On October 25, 2024, the 21st World Congress of Chinese Medicine (WCCM) commenced at the United Nations Educational, Scientific and Cultural Organization (UNESCO) Headquarters in Paris, France. A key highlight of the WCCM was the Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases on October 26. Hosted by the...
Blackmores Celebrates Gold Win with Trusted Brands 2024
With over 90 years of legacy, Blackmores Continues to Elevate Natural Health as one of Singaporeans' Most Trusted Health Supplement Brand SINGAPORE, Oct. 29, 2024 /PRNewswire/ -- BLACKMORES, pioneer in natural health, is proud to announce its recognition as a Gold brand in the prestigious Trusted Brands 2024 Awards. This accolade, voted by Singaporean consumers, reaffirms Blackmores' unwavering commitment to...
Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics
SAN FRANCISCO and SUZHOU, China, Oct. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces the latest clinical results of a multicenter, open-label Phase 2 study (ClinicalTrials.gov, NCT05970978) of picankibart (R&D code:...
Asia CEO Awards Adds USANA Philippines to Their Circle of Excellence
MANILA, Philippines, Oct. 29, 2024 /PRNewswire/ -- USANA Health Sciences, Inc. and its Philippines market were recently added to the illustrious Circle of Excellence from the Asia CEO Awards. The Circle of Excellence recognizes the top companies in the Philippines that have shown success and value in the development of the country's...
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK’s AREXVY
-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for Clover's non-adjuvanted SCB-1019 matched GSK's AS01E-adjuvanted AREXVY in older adults, while demonstrating significantly better tolerability compared to AREXVY -- -- Clover plans to initiate clinical trials in 2025 evaluating SCB-1019 in an RSV...
